K

Kiniksa Pharmaceuticals Ltd
D

KNSA

77.240
USD
-2.10
(-2.65%)
مغلق
حجم التداول
18,546
الربح لكل سهم
1
العائد الربحي
-
P/E
78
حجم السوق
6,026,574,764
أصول ذات صلة المقالات
المزيد

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: الرعاية الصحية
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.